



Contact:

CCG Investor Relations

Crocker Coulson, President

Phone: +1-646-213-1915 (New York)

E-mail: [crocker.coulson@ccgir.com](mailto:crocker.coulson@ccgir.com)

Web: [www.ccgirasia.com](http://www.ccgirasia.com)

*For Immediate Release*

## **China-Biotics, Inc. Receives Manufacturing Certificate for New Products**

**Shanghai, China – January 20, 2009** – China-Biotics, Inc. (Nasdaq: CHBT) (“China-Biotics,” “the Company”), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced the State Food and Drug Administration has approved manufacturing certificates for the production of several new products, including Synbiotics Capsules, Probiotics Gegen Capsules, Probiotics Tremella Polysaccharide Capsules and Probiotics Chewable Tablets.

“These new certificates will enable us to successfully expand our product portfolio,” said Mr. Jinan Song, China-Biotics’ Chairman and Chief Executive Officer. “The launch of the new products will better serve our existing customers and support our continuing regional retail expansion.”

The new probiotics-based products were developed during an eight-month process and are currently in production at the Company’s existing manufacturing facility.

The products are intended to offer several different health solutions to consumers. Synbiotics Capsules’ primary active ingredients are lactobacillus thermophilus, infant bifidobacterium, bifidobacterium bifidum and oligo-fructose, which can enhance adolescents’ immune systems and gastrointestinal (“GI”) health. Probiotics Gegen Capsules’ primary active ingredients are lactobacillus acidophilus and bifidobacterium bifidum (“LA-BB”) and gegen powder, a traditional Chinese medicinal herb, which can enhance women’s GI health and relieve menopausal symptoms. Probiotics Tremella Polysaccharide Capsules’ primary active ingredients are LA-BB and tremella polysaccharide, which can enhance the GI health and immune systems of seniors. Probiotics Chewable Tablets’ primary active ingredients are lactobacillus acidophilus, infant bifidobacterium and taurine, which can reduce the creation of enteric pathogenic bacteria and increase consumers’ energy levels.

“For the past few years, we have devoted significant resources in the research and development of different kinds of new products, as well as educating the public about the benefits of probiotics,” said Mr. Song. “In addition to an in-house R&D team of more than 30 researchers, we also have extensive relationships with academic institutions, including a post-doctoral research center in partnership with the Northeast Agricultural University of China. Our success has attracted and will continue to attract more talented people to health-related careers with China-Biotics. This success will enable us to further

promote probiotics-based products through our R&D capabilities and our in-depth knowledge of the nutritional supplement market in China.”

### **About China-Biotics, Inc.**

China-Biotics, Inc. (“China-Biotics,” “the Company”), a leading manufacturer of biotechnology products and supplements, engages in the research, development, marketing and distribution of probiotics dietary supplements. Through its wholly owned subsidiary, Shanghai Shining Biotechnology Co., Ltd., the Company has operations in Shanghai. Its proprietary product portfolio contains live microbial nutritional supplements under the “Shining” brand. Currently, the products are sold OTC through large distributors to pharmacies and supermarkets in Shanghai, Jiangsu, and Zhejiang. China-Biotics plans to launch 300 Shining brand retail outlets in major cities in China. Currently, China-Biotics is strategically expanding its production capacity of probiotics to meet growing demand in the bulk additive market. For more information, please visit <http://www.chn-biotics.com>.

*Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company’s ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, market acceptance of its retail store concept, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

###